Mitral and Aortic Valve Prosthetic Endocarditis After Percutaneous Closure of Mitral Paravalvular Leak

2013 ◽  
Vol 95 (2) ◽  
pp. e45-e46
Author(s):  
Pietro Giorgio Malvindi ◽  
Giuseppe Maria Raffa ◽  
Antioco Cappai ◽  
Alessandro Barbone ◽  
Alessio Basciu ◽  
...  
2020 ◽  
Vol 4 (3) ◽  
pp. 1-6
Author(s):  
Reda Abuelatta ◽  
Lamiaa Khedr ◽  
Ibraheem AlHarbi ◽  
Hesham A Naeim

Abstract Background Haemolytic anaemia is a complication of paravalvular leak (PVL). The correlation between the size of the leak and the severity of haemolysis is unclear. Small leaks can cause severe haemolysis, whereas significant leaks may cause no haemolysis. Case summary We report the case of a 40-year-old male who underwent mechanical mitral and aortic valve replacement 20 years ago. In the last 3 years, the procedure was repeated three times due to infective endocarditis. He presented with severe shortness of breath. A transoesophageal echocardiogram with three-dimensional surgical view showed that both discs of the mechanical mitral valve opened sufficiently but a severe PVL had occurred at the 9–12 o’clock position. The location of the mitral valve was abnormal, the sewing ring was inserted high at the mid-interatrial septum. The mechanical aortic valve functioned well. Closure of the transcutaneous PVL was accomplished with two percutaneously implanted devices, leaving a small leak in between. After closure, he developed haemolytic anaemia (haemoglobin: 6 g/dL, lactate dehydrogenase: 1896 units/L, reticulocyte count: 4.6%). He then received 16 units of packed red blood cells. He developed acute kidney injury and was started on haemodialysis. We then installed two additional devices to completely close the mild residual leak and another device to resolve the bidirectional transseptal defect. After 2 days, his renal function returned to normal and anaemia improved (haemoglobin: 9.1 g/dL). Discussion Mild residual paravalvular leak can cause severe haemolytic anaemia that is correctable via percutaneous closure of the leak.


2015 ◽  
Vol 24 (9) ◽  
pp. 936-939 ◽  
Author(s):  
Marco Luciano Rossi ◽  
Guido Belli ◽  
Paolo Pagnotta ◽  
Carla Lucarelli ◽  
Patrizia Presbitero

2020 ◽  
Vol 29 ◽  
pp. S34
Author(s):  
C. McAlister ◽  
R. Troughton ◽  
T. Clendon ◽  
J. Blake ◽  
D. Smyth ◽  
...  

2016 ◽  
Vol 43 (2) ◽  
pp. 137-141 ◽  
Author(s):  
Daxin Zhou ◽  
Wenzhi Pan ◽  
Lihua Guan ◽  
Juying Qian ◽  
Junbo Ge

The presence of a mechanical aortic valve prosthesis has been considered a contraindication to retrograde percutaneous closure of mitral paravalvular leaks, because passing a catheter through the mechanical aortic valve can affect the function of a mechanical valve and thereby lead to severe hemodynamic deterioration. We report what we believe are the first 2 cases of retrograde transcatheter closure of mitral paravalvular leaks through a mechanical aortic valve prosthesis without transseptal or transapical puncture. Our experience shows that retrograde transcatheter closure of mitral paravalvular leaks in this manner can be an optional approach for transcatheter closure of such leaks, especially when a transapical or transseptal puncture approach is not feasible. This technique might also be applied to other transcatheter procedures in which there is a need to pass a catheter through a mechanical aortic valve prosthesis.


2014 ◽  
Vol 30 (6) ◽  
pp. 696.e9-696.e11 ◽  
Author(s):  
Miroslava Stolcova ◽  
Italo Porto ◽  
Francesco Meucci ◽  
Giovanni Squillantini ◽  
Gennaro Santoro

Author(s):  
Helge Möllmann ◽  
David M. Holzhey ◽  
Michael Hilker ◽  
Stefan Toggweiler ◽  
Ulrich Schäfer ◽  
...  

Abstract Background Transcatheter aortic valve implantation (TAVI) has become standard treatment for elderly patients with symptomatic severe aortic valve stenosis. The ACURATE neo AS study evaluates 30-day and 1-year clinical and hemodynamic outcomes in patients treated with the ACURATE neo2 valve. Methods The primary endpoint of this single-arm multicenter study is 30-day all-cause mortality. Other key endpoints include device performance, echocardiographic measures assessed by an independent core laboratory, and VARC-2 clinical efficacy and safety endpoints through 12 months. Results The study enrolled 120 patients (mean age 82.1 ± 4.0 years; 67.5% female, mean baseline STS score 4.8 ± 3.8%). The VARC-2 composite safety endpoint at 30 days occurred in 13.3% of patients. All-cause mortality was 3.3% at 30 days and 11.9% at 1 year. The 30-day stroke rate was 2.5% (disabling stroke 1.7%); there were no new strokes between 30 days and 12 months. The rate of permanent pacemaker implantation was 15.0% (18/120) at 30 days and 17.8% (21/120) at 1 year. No patients required re-intervention for valve-related dysfunction and there were no cases of valve thrombosis or endocarditis. Patients demonstrated significant improvement in mean aortic valve gradient (baseline 38.9 ± 13.1 mmHg, 1 year 7.8 ± 3.5 mmHg; P < 0.001 in a paired analysis). In the overall population, paravalvular leak was evaluated at 1 year as none/trace in 60.5%, mild in 37.0%, and moderate in 2.5%; no patients had severe PVL. Conclusions One-year outcomes from the ACURATE neo AS study support the safety and performance of TAVI with the ACURATE neo2 valve. Graphic Abstract


Sign in / Sign up

Export Citation Format

Share Document